Announcement • Apr 21
Epigenomics AG, Annual General Meeting, May 27, 2026 Epigenomics AG, Annual General Meeting, May 27, 2026, at 09:00 W. Europe Standard Time. Announcement • Apr 03
Epigenomics AG to Report Fiscal Year 2025 Results on Apr 02, 2026 Epigenomics AG announced that they will report fiscal year 2025 results on Apr 02, 2026 Announcement • Jul 17
Epigenomics AG, Annual General Meeting, Aug 27, 2025 Epigenomics AG, Annual General Meeting, Aug 27, 2025, at 10:30 W. Europe Standard Time. New Risk • May 06
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€5.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€5.7m free cash flow). Negative equity (-€8.0m). Revenue is less than US$1m (€339k revenue, or US$365k). Market cap is less than US$10m (€1.43m market cap, or US$1.54m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€500k net loss in 2 years). Shareholders have been diluted in the past year (7.5% increase in shares outstanding). New Risk • Mar 24
New major risk - Negative shareholders equity The company has negative equity. Total equity: -€8.0m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€8.0m). Revenue is less than US$1m (€339k revenue, or US$367k). Market cap is less than US$10m (€1.57m market cap, or US$1.69m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€5.7m). Currently unprofitable and not forecast to become profitable over next 2 years (€600k net loss in 2 years). Shareholders have been diluted in the past year (6.3% increase in shares outstanding). New Risk • Feb 26
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (€447k revenue, or US$484k). Market cap is less than US$10m (€1.41m market cap, or US$1.52m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-€14m). Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€595k net loss in 2 years). Share price has been volatile over the past 3 months (9.5% average weekly change). Shareholders have been diluted in the past year (4.2% increase in shares outstanding). Announcement • Oct 12
New Day Diagnostics, LLC acquired Substantially all of Assets of Epigenomics AG for $9.8 million. New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG for $9.8 million on July 24, 2023. Under the terms of consideration, As consideration for the sale, Epigenomics AG will receive a purchase price of up to USD 12.05 million, which can be broken down as follows: Cash payments of USD 1.8 million: USD 0.5 million on the closing date, USD 1.0 million on December 1, 2023 and USD 0.3 million on June 30, 2024. Further cash payments of up to USD 8.0 million contingent on the achievement of certain milestones related to Epi proColon and foremost Epi proColon “Next-Gen”. An interest in the acquirer of 3.0%, valued at least at USD 2.25 million. In addition, the Company will receive royalty or earn-out payments, in the form of royalties linked to the commercialization of the “Next-Gen”-Test. These payments extend probably until October 2043, the year in which patent protection for the product is expected to expire. Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property along with all patents as well as the entire biobank, and thus all of its assets within the meaning of Section 179a of the German Stock Corporation Act (AktG), to the acquirer. The acquisition would expand New Day Diagnostics' portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer. The agreement is subject to certain closing conditions, including the approval at the Company’s Extraordinary General Meeting. The sale of the assets to New Day Diagnostics is expected to enable the commercialization of Epi proColon “Next-Gen” and secure future cash flows for Epigenomics AG. As of September 14, 2023, Extraordinary General Meeting of Epigenomics approved the transaction. The closing of the agreement remains subject to customary closing conditions, and both parties are diligently working towards its completion.
TCB Capital Advisors, an affiliate of Weild & Co., acted as the exclusive financial advisor to New Day Diagnostics on this transaction, and Brock Shipe Klenk PLC, Orrick Herrington & Sutcliffe LLP, and Merchant & Gould acted as New Day Diagnostics' legal advisors.
New Day Diagnostics, LLC completed the acquisition of Substantially all of Assets of Epigenomics AG on October 10, 2023. Reported Earnings • Aug 13
Second quarter 2023 earnings released: €0.62 loss per share (vs €0.32 loss in 2Q 2022) Second quarter 2023 results: €0.62 loss per share (further deteriorated from €0.32 loss in 2Q 2022). Revenue: €70.0k (down 44% from 2Q 2022). Net loss: €2.63m (loss widened 102% from 2Q 2022). Revenue is forecast to grow 76% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Buying Opportunity • Aug 03
Now 29% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be €0.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 75%. Revenue is forecast to decline by 25% in 2 years. Earnings is forecast to decline by 106% in the next 2 years. Announcement • Jul 26
New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG. New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG on July 24, 2023. Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property. The acquisition would expand New Day Diagnostics' portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer.TCB Capital Advisors, an affiliate of Weild & Co., acted as the exclusive financial advisor to New Day Diagnostics on this transaction, and Brock Shipe Klenk PLC, Orrick Herrington & Sutcliffe LLP, and Merchant & Gould acted as New Day Diagnostics' legal advisors. Buying Opportunity • Jul 19
Now 24% undervalued Over the last 90 days, the stock is up 14%. The fair value is estimated to be €0.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Earnings per share has grown by 75%. Revenue is forecast to decline by 25% in 2 years. Earnings is forecast to decline by 106% in the next 2 years. Announcement • Jun 13
Epigenomics Shares Surge on Talks to Sell Nearly All Assets for $11.5m Epigenomics AG (XTRA:ECX1) shares more than doubled in value on June 12, 2023 after it said it is holding talks with an unidentified U.S. company to sell nearly all of its assets for around $11.5 million. The German medical diagnostic company said the potential deal, which is unbinding and therefore could still fail, relates to the patents and other rights of its blood tests to screen for colon cancer and all blood samples owned by Epigenomics. Current negotiations place the deal closing in December, Epigenomics said. The unidentified acquirer would also have to pay royalties and other costs associated with the potential commercialization of a diagnostic test in development. Price Target Changed • Jun 02
Price target increased by 9.1% to €6.00 Up from €5.50, the current price target is provided by 1 analyst. New target price is 926% above last closing price of €0.58. Stock is down 68% over the past year. The company is forecast to post a net loss per share of €1.63 next year compared to a net loss per share of €2.96 last year. Reported Earnings • Jun 01
First quarter 2023 earnings released: €1.31 loss per share (vs €0.67 loss in 1Q 2022) First quarter 2023 results: €1.31 loss per share (further deteriorated from €0.67 loss in 1Q 2022). Net loss: €5.59m (loss widened 110% from 1Q 2022). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Announcement • May 20
Epigenomics AG Announces Resignation of Andrew Lukowiak from the Company and the Executive Board Effective May 31, 2023 Epigenomics AG announced that Member of the Executive Board, President, and Chief Scientific Officer Dr. Andrew Lukowiak, and the Company's Supervisory Board agreed on his resignation from the Company and the Executive Board effective May 31, 2023. Between now and the resignation date Dr. Lukowiak will continue to support the Company’s restructuring efforts in coordination with the Supervisory Board. The Company continues to be committed to maximizing the value of its technology through corporate partnering, licensing and/or asset sales. Dr. Lukowiak has been a Member of the Executive Board, President, and CSO of Epigenomics AG since December 2021. His broad contributions across the organization have been instrumental in furthering the Company’s colorectal cancer diagnostics’ program, including his systematic optimization of R&D structure and processes, as well as his execution of complementary partnerships. However, in recent months, in the current capital market environment, the Company has been unable to raise additional capital to secure funding for the FDA pivotal study of the "Next-Gen" test. In response, the restructuring of the Company was initiated on February 15, 2023 to minimize costs. Against this backdrop, the resignation of Dr. Andrew Lukowiak now also takes place. Reported Earnings • May 01
Full year 2022 earnings released: €2.96 loss per share (vs €0.87 loss in FY 2021) Full year 2022 results: €2.96 loss per share (further deteriorated from €0.87 loss in FY 2021). Net loss: €12.0m (loss widened 395% from FY 2021). Revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Germany. Breakeven Date Change • Dec 22
No longer forecast to breakeven The 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €25.8m in 2024. Breakeven Date Change • Nov 16
No longer forecast to breakeven The 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €11.2m in 2024. Reported Earnings • Nov 11
Third quarter 2022 earnings released Third quarter 2022 results: €0.10 loss per share. Net loss: €1.56m (down 155% from profit in 3Q 2021). Revenue is forecast to grow 73% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Germany. Reported Earnings • Aug 15
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: €126.0k (up 7.7% from 2Q 2021). Net loss: €1.30m (loss narrowed 44% from 2Q 2021). Over the next year, revenue is expected to shrink by 91% compared to a 12% growth forecast for the Biotechs industry in Germany. Price Target Changed • Jun 01
Price target increased to €1.07 Up from €0.95, the current price target is an average from 2 analysts. New target price is 117% above last closing price of €0.49. Stock is down 72% over the past year. The company is forecast to post a net loss per share of €0.99 next year compared to a net loss per share of €0.22 last year. Reported Earnings • May 14
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: €0.17 loss per share. Revenue: €115.0k (up 8.5% from 1Q 2021). Net loss: €2.66m (loss widened 121% from 1Q 2021). Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) also surpassed analyst estimates by 41%. Over the next year, revenue is expected to shrink by 91% compared to a 36% growth forecast for the industry in Germany. Price Target Changed • Apr 27
Price target decreased to €0.95 Down from €1.14, the current price target is an average from 2 analysts. New target price is 106% above last closing price of €0.46. Stock is down 63% over the past year. The company is forecast to post a net loss per share of €1.02 next year compared to a net loss per share of €0.22 last year. Breakeven Date Change • Apr 27
No longer forecast to breakeven The 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €11.2m in 2024. Breakeven Date Change • Apr 06
No longer forecast to breakeven The 2 analysts covering Epigenomics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.4m in 2024. New consensus forecast suggests the company will make a loss of €11.2m in 2024. Price Target Changed • Mar 28
Price target decreased to €0.95 Down from €1.14, the current price target is an average from 2 analysts. New target price is 77% above last closing price of €0.54. Stock is down 79% over the past year. The company is forecast to post a net loss per share of €1.02 next year compared to a net loss per share of €0.22 last year. Price Target Changed • Jan 23
Price target decreased to €1.14 Down from €1.39, the current price target is an average from 2 analysts. New target price is 122% above last closing price of €0.51. Stock is down 80% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €2.02 last year. Is New 90 Day High Low • Mar 07
New 90-day low: €2.19 The company is down 39% from its price of €3.57 on 07 December 2020. The German market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.33 per share. Is New 90 Day High Low • Jan 31
New 90-day low: €2.27 The company is down 53% from its price of €4.80 on 02 November 2020. The German market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.76 per share. Price Target Changed • Dec 16
Price target lowered to €23.73 Down from €32.80, the current price target is an average from 3 analysts. The new target price is 638% above the current share price of €3.22. As of last close, the stock is down 71% over the past year.